New disulfiram derivatives as magl-selective inhibitors

5/30/2021 Monoacylglycerol lipase (MAGL) is a key enzyme in the human endocannabinoid system. It is also the main enzyme responsible for the conversion of 2-arachidonoyl glycerol (2-AG) to arachidonic acid (AA), a precursor of prostaglandin synthesis. The inhibition of MAGL activity would be beneficial for the treatment of a wide range of diseases, such as inflammation, neurodegeneration, metabolic disorders and cancer. Here, the author reports the pharmacological evaluation of new disulfiram derivatives as potent inhibitors of MAGL. These analogues displayed high inhibition selectivity over fatty acid amide hydrolase (FAAH), another endocannabinoid-hydrolyzing enzyme. In particular, compound 2i inhibited MAGL in the low micromolar range. However, it did not show any inhibitory activity against FAAH.

Other Researches


Kirenol: A promising bioactive metabolite from siegesbeckia species: A detailed review

Read More


Repurposing of Some Natural Product Isolates as SARS-COV-2 Main Protease Inhibitors via In Vitro Cell Free and Cell-Based Antiviral Assessments and Molecular Modeling Approaches

Read More


Nitric-Oxide-Mediated Vasodilation of Bioactive Compounds Isolated from Hypericum revolutum in Rat Aorta

Read More


Natural Products of the Fungal Genus Humicola: Diversity, Biological Activity, and Industrial Importance

Read More


Jojoba oil: An updated comprehensive review on chemistry, pharmaceutical uses, and toxicity

Read More


Vasodilating effect of Hypericum revolutum (Vahl) (Clusiaceae) methanol extract in rats

Read More

Cookies Policy

This website uses cookies to improve your user experience. By accepting and closing when first visiting the page you consent to our use of cookies